United States Drug Delivery Systems Market Size, Share, and COVID-19 Impact Analysis, By Device Type (Advanced and Conventional), By Type (Injectable, Transdermal, Inhalation, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others), and US Drug Delivery Systems Market Insights, Industry Trend, Forecasts to 2035

USA Drug Delivery Systems Market Insights Forecasts to 2035

• The US Drug Delivery Systems Market Size was Estimated at USD 17.03 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.51% from 2025 to 2035
• The USA Drug Delivery Systems Market Size is Expected to reach USD 27.68 Billion by 2035

According to a Research Report Published by Spherical Insights & Consulting, The US Drug Delivery Systems Market Size is anticipated to reach USD 27.68 Billion by 2035, Growing at a CAGR of 4.51% from 2025 to 2035. The market size growth is attributed to the increasing prevalence of chronic diseases such as diabetes, epilepsy, cancer, COPD, etc., rising focus on formulation research and development studies, and growing need for targeted therapies for the effective treatment of the diseases.

Market Overview

The United States Drug Delivery Systems Market Size emphasizes the development and commercialization of drug delivery systems or technologies that are used for the effective penetration and absorption of the active pharmaceutical ingredients (API) into specific tissue, cells, or organs, for the management of diseases. Drug delivery systems are technological advancements that regulate the body's drug metabolism to produce the best possible therapeutic outcomes. These are tools or mixtures that provide active medicinal substances in a precise manner, enhancing the ingredients' efficacy and safety. By improving therapeutic selectivity and lowering systemic toxicity, nano-derived drug delivery devices significantly advance precision medicine. Inflammation-related illnesses like cancer, heart disease, and neurological disorders can be effectively treated using these systems. The optimal drug delivery system should increase the therapeutic agent's pharmacokinetic profile and bioavailability. The drug delivery systems include the autoinjectors, transdermal patch, nasal spray, niosomes, exosomes, liposomes, etc. The market for drug delivery systems is expanding as a result of the need for controlled, targeted healthcare delivery. These methods improve patient outcomes by reducing adverse effects and increasing medication efficacy, these methods improve patient outcomes. The incidence of chronic diseases, technological developments, and individualized medicine are important market drivers.

Report Coverage

This research report categorizes the market for the US drug delivery systems market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the US drug delivery systems market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US drug delivery systems market.

Driving Factors

Increasing prevalence of chronic diseases and advancements in the drug delivery systems:

There is a rising need for precise drug delivery systems due to the prevalence of chronic illnesses like diabetes, cancer, and respiratory and cardiovascular disorders. The market for drug delivery systems in the USA is growing as medical professionals look for cutting-edge ways to treat these chronic illnesses. The healthcare industry is undergoing a change thanks to technological developments like targeted delivery methods, nanotechnology, microencapsulation, and smart medication delivery systems. These methods reduce side effects, increase bioavailability, and improve drug delivery efficiency. By delivering drugs directly to sick cells, targeted delivery systems reduce damage to healthy tissue. Real-time monitoring and dosage modifications are made possible by wearable drug delivery systems, which enhance patient compliance and results. These technologies advance the market by enhancing the effectiveness of medications and opening the door for novel therapeutic approaches. The rising investments in R&D to improve drug delivery systems drive the market to unprecedented heights.

Upsurge in the self-administration and patient compliance:

Drug self-administration is growing in prominence due to its convenience and economy. Patients are choosing tools like autoinjectors, inhalers, and portable infusion pumps as part of the growing trend of managing chronic illnesses at home. The need for approachable solutions that increase patient authority and compliance is driving the market growth. To guarantee patient adherence to their medication regimens, the US drug delivery system market sector is concentrating on creating user-friendly methods, including injectable devices and oral and transdermal patches.

Restraining Factors

The regulatory challenges, high development costs, limited patient awareness, inconsistent reimbursement policies, manufacturing complexity, increasing costs, and time-to-market may restrict the market growth.

Market Segmentation

The USA drug delivery systems market share is classified into device type, type, and distribution channel.

• The conventional segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US drug delivery systems market is segmented by device type into advanced and conventional. Among these, the conventional segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment growth is attributed to the longer shelf life, provision of dose adjustments, cost-effectiveness, ease of administration, improved in-vitro-in-vivo correlation, non-invasiveness, and accurate dosage.

• The injectable segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US drug delivery systems market is segmented by type into injectable, transdermal, inhalation, and others. Among these, the injectable segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment dominance is attributed to the following factors, such as uniform absorption and distribution of drugs, enhanced bioavailability, effective, does not undergo first pass metabolism, and rising vaccination programs by government and private organizations.

• The hospital pharmacies segment dominated the United States drug delivery systems market in 2024 and is predicted to grow at a significant CAGR during the forecast period.

The US drug delivery systems market is segmented by distribution channel into retail pharmacies, hospital pharmacies, and others. Among these, the hospital pharmacies segment dominated the United States drug delivery systems market in 2024 and is predicted to grow at a significant CAGR during the forecast period. The rising surgical procedures, growing hospital admissions, and patient visits escalate the demand for drug delivery systems, which leads to the segment's growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US drug delivery systems market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Baxter International
• Teva Pharmaceuticals
• Becton Dickinson & Company
• Pfizer
• AbbVie
• Johnson & Johnson
• Others

Recent Developments:

• In May 2025, DEBRA Research and Dermaliq Therapeutics signed a strategic partnership to develop advanced topical treatments for epidermolysis bullosa using Dermaliq's proprietary hyliQ technology platform, aiming to enhance drug delivery.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the US drug delivery systems market based on the below-mentioned segments:

US Drug Delivery Systems Market, By Device Type

• Advanced
• Conventional

US Drug Delivery Systems Market, By Type

• Injectable
• Transdermal
• Inhalation
• Others

US Drug Delivery Systems Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Others